KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Payables (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Payables data on record, last reported at $29.9 million in Q4 2025.

  • For Q4 2025, Payables rose 190.29% year-over-year to $29.9 million; the TTM value through Dec 2025 reached $29.9 million, up 190.29%, while the annual FY2025 figure was $29.9 million, 190.29% up from the prior year.
  • Payables reached $29.9 million in Q4 2025 per AQST's latest filing, up from $10.9 million in the prior quarter.
  • Across five years, Payables topped out at $29.9 million in Q4 2025 and bottomed at $5.7 million in Q2 2024.
  • Average Payables over 5 years is $10.4 million, with a median of $10.0 million recorded in 2022.
  • Peak YoY movement for Payables: plummeted 52.54% in 2021, then soared 190.29% in 2025.
  • A 5-year view of Payables shows it stood at $8.3 million in 2021, then rose by 19.63% to $9.9 million in 2022, then decreased by 10.26% to $8.9 million in 2023, then rose by 15.25% to $10.3 million in 2024, then skyrocketed by 190.29% to $29.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $29.9 million in Q4 2025, $10.9 million in Q3 2025, and $12.0 million in Q2 2025.